Vera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INC

Financial Performance:

• Revenue and financial metrics were not detailed in this specific transcript segment; commercial sales of the approved product, TruTacna (atacicept), launched in the U.S. following accelerated approval on July 7, with an update on Q3 results and earnings scheduled for November.
• Cash flow, debt, profit margins, and deferred revenue were not disclosed in the call.

Guidance and Future Outlook:

• Regulatory Timeline: Submission of the supplemental Biologics License Application (sBLA) for full approval is underway this quarter; FDA review is anticipated, with full approval and label updates targeted for mid-2027.
• Commercial Strategy: Full commercial detailing and sales force expansion are expected to inflect significantly upon obtaining the full approval label in 2027, building on current adoption of the accelerated approval indication.
• Pipeline Expansion: Additional data on TruTacna in adolescents with IgA nephropathy and in membranous nephropathy (autoantibody-driven) are being presented; long-term data collection will continue in open-label extensions through week 156.
• Clinical Trial Paradigm: Vera Therapeutics is pioneering a 52-week GFR endpoint strategy for future approvals, demonstrating feasibility for earlier readouts of disease-modifying therapies.

Business Segments and Product Lines:

• Core Product (TruTacna/Atacicept): A fusion protein (BAFF/APRIL inhibitor) for IgA nephropathy; currently marketed in the U.S. under accelerated approval.
• ORIGIN-3 Trial Results: Final efficacy data published in the New England Journal of Medicine; the trial met all pre-specified endpoints including a 5.0 mL/min/year placebo-adjusted annualized eGFR slope difference and a 76% reduction in the composite kidney disease progression endpoint at 104 weeks.
• Clinical Positioning: Demonstrates a return to physiological kidney function loss (<1 mL/min/year) in high-risk patients, contrasting with 10% annual loss in the placebo group on supportive care alone.
• New Indications: Ongoing evaluation in adolescent populations and adjacent kidney diseases (membranous nephropathy).

Market and Competitive Landscape:

• Competitive Context: Compared favorably to other Phase 3 data (e.g., Semiphlimab/Voizet), with ORIGIN-3 featuring the highest-risk patient population recruited to date (mean GFR ~65 mL/min, ~2.2g proteinuria) despite optimized standard of care.
• Market Validation: Two independent global trials targeting Baff and APRIL have validated the dual-inhibition mechanism with consistent efficacy and safety profiles.
• Treatment Paradigm Shift: Moving the standard of care from "watchful waiting" and steroid use to immediate combination therapy (disease-modifying Atacicept + CKD supportive care) to prevent lifetime kidney failure risk.
• Unmet Need: Current supportive care (RAS inhibitors/SGLT2 inhibitors) only offers limited risk reduction (16-55%); Atacicept addresses the root cause (dysregulated B-cell function) and eliminates risk of dialysis/transplant within the study period.

Risks and Challenges:

• Safety Monitoring: Continued need for long-term follow-up to assess lifelong safety, though no serious adverse events (SAEs), deaths, or clinically relevant hypogammoglobulinemia/opportunistic infections occurred in the trial.
• Anti-Drug Antibodies (ADAs): Observed in nearly 50% of patients but deemed clinically irrelevant as they did not impact PK/PD, safety, or efficacy.
• Dosing Frequency: Current regimen is weekly subcutaneous injection; an ongoing study is evaluating alternative dosing frequencies (e.g., monthly) to improve patient convenience.
• Diagnostic Delay: Many patients are diagnosed late with significant prior kidney damage; industry efforts are focused on earlier detection and biopsy rates.

Management Commentary and Tone:

• Tone: Highly confident and celebratory; CEO Marshall Fordyce described the data as a "paradigm shift" and "transformative," marking the first therapy capable of normalizing GFR loss in IgA nephropathy.
• Strategic Confidence: Management emphasized that the 52-week endpoint strategy was a calculated, patient-centric decision that preserved trial integrity while demonstrating robust efficacy.
• Commercial Outlook: Chief Commercial Officer expressed confidence in a significant sales inflection point post-full approval, leveraging the pivotal data and NEJM publication for rapid market adoption.

Analyst Questions and Answers:

• Comparator Data (Semiphlimab): Dr. Barrett clarified that direct comparison is difficult due to differences in patient risk profiles, trial duration, and composite endpoint definitions; ORIGIN-3 included the sicker population.
• Dual vs. Single Target: Evidence suggests dual inhibition (BAFF/APRIL) is more effective than single-target approaches, with two independent trials confirming the mechanism.
• Proteinuria vs. GFR: A key discussion point was the "decoupling" of proteinuria reduction and GFR protection; Atacicept stabilizes GFR even with residual proteinuria, a phenomenon not seen with hemodynamic agents.
• Future Trial Design: FDA alignment confirmed feasibility of using 52-week GFR slopes as primary endpoints for future approvals, setting a new industry standard.
• Subgroup Analysis: Treatment effect was consistent across all pre-specified subgroups (age, region, baseline GFR, proteinuria levels, background therapy).
• Long-term Safety: Anti-drug antibodies were monitored extensively and found to have no clinical impact; long-term data collection continues.

Other Key Points:

• Patient-Centric Trial Design: The trial was unblinded early for all placebo patients (who were losing kidney function rapidly) to allow them to access active therapy, resulting in a 3x higher discontinuation rate in the placebo arm due to disease progression.
• Steroid Reduction: Clinicians are reportedly moving away from toxic steroid regimens toward Atacicept as a safer, more effective alternative for long-term management.
• Prevalence Awareness: Industry efforts are shifting to promote earlier diagnosis, with estimates suggesting the true prevalence of IgA nephropathy may be double current biopsy-proven figures.
• Publication Status: Full efficacy data and publication in the New England Journal of Medicine occurred simultaneously with the plenary presentation at the American Society of Nephrology (ASN) meeting.